The findings from multiple clinical studies, such as PERTAIN, CLEOPATRA [39], and PERUSE [40], consistently confirmed that targeting HER2-positive breast cancer with two different monoclonal antibodies, pertuzumab and trastuzumab, leads to a more comprehensive blockade of HER2 signaling compared to treatment with either antibody alone. This evidence concerns the gene ERBB2 and breast cancer.